54,925 results match your criteria multiple myeloma

Periocular cutaneous amyloidosis in multiple myeloma.

QJM 2021 Apr 20. Epub 2021 Apr 20.

Department of Dermatology, Venereology and Leprology.

View Article and Full-Text PDF

Ehrlichia-induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant.

Transpl Infect Dis 2021 Apr 20:e13621. Epub 2021 Apr 20.

The Myeloma Center, Division of Hematology/Oncology, UAMS.

Hemophagocytic lymphohistiocytosis (HLH) causes multi-organ failure due to the release of multiple cytokines mediating widespread inflammation. We present a patient with multiple myeloma on maintenance chemotherapy with the anti-CD38 monoclonal antibody daratumumab after autologous stem cell transplant (ASCT) who developed fatal HLH secondary to Ehrlichiosis. Read More

View Article and Full-Text PDF

Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.

Curr Hematol Malig Rep 2021 Apr 19. Epub 2021 Apr 19.

Division of Hematology/Oncology, Department of Medicine, Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, 161 Fort Washington Ave G, New York, NY, 10032, USA.

Purpose Of Review: With rapid advances in the therapeutic landscape and biological insights in multiple myeloma, it is critical to identify and strategically manage high-risk patients to achieve best outcomes with currently available drugs. The purpose of this review is to summarize the management of high-risk myeloma with a focus on recent advances in the field.

Recent Findings: The most widely accepted definition of "high-risk" is the Revised International Staging System (R-ISS) stage 3 disease, which includes high tumor burden (ISS stage 3) and high-risk FISH cytogenetics or an elevated lactate dehydrogenase level. Read More

View Article and Full-Text PDF

Germline variants at SOHLH2 influence multiple myeloma risk.

Blood Cancer J 2021 Apr 19;11(4):76. Epub 2021 Apr 19.

Hematology and Transfusion Medicine, Department of Laboratory Medicine, 221 84, Lund, Sweden.

Multiple myeloma (MM) is caused by the uncontrolled, clonal expansion of plasma cells. While there is epidemiological evidence for inherited susceptibility, the molecular basis remains incompletely understood. We report a genome-wide association study totalling 5,320 cases and 422,289 controls from four Nordic populations, and find a novel MM risk variant at SOHLH2 at 13q13. Read More

View Article and Full-Text PDF

A gastric lesion revealing plasma cell dyscrasia: a rare case.

Gastroenterol Hepatol 2021 Apr 16. Epub 2021 Apr 16.

Department of Gastroenterology, Centro Hospitalar Universitário de São João, 4200-427 Porto, Portugal; WGO Training Center, 4200-427 Porto, Portugal; Faculty of Medicine of the University of Porto, 4200-427 Porto, Portugal. Electronic address:

View Article and Full-Text PDF

Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma.

Drugs 2021 Apr 19. Epub 2021 Apr 19.

Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA.

The plasma cell neoplasm multiple myeloma (MM) is currently considered incurable. However, significant advances in treatment options over the past 20 years have led to unprecedented response rates to initial therapy as well as prolonged survival rates. Induction regimens have evolved from alkylator-based therapies to those consisting of immunomodulatory drugs and proteasome inhibitors. Read More

View Article and Full-Text PDF

Did COVID-19 related delays in surgical management lead to patient morbidity in the orthopaedic oncological population?

Bone Jt Open 2021 Apr;2(4):236-242

Department of Orthopaedics, North Shore-Long Island Jewish Hospital, Northwell Health Medical Center, New Hyde Park, New York, USA.

Aims: The aim of this study was to assess orthopaedic oncologic patient morbidity resulting from COVID-19 related institutional delays and surgical shutdowns during the first wave of the pandemic in New York, USA.

Methods: A single-centre retrospective observational study was conducted of all orthopaedic oncologic patients undergoing surgical evaluation from March to June 2020. Patients were prioritized as level 0-IV, 0 being elective and IV being emergent. Read More

View Article and Full-Text PDF

Solitary bone plasmacytoma of the upper cervical spine: A case report.

World J Clin Cases 2021 Apr;9(10):2380-2385

Department of Orthopaedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China.

Background: Solitary bone plasmacytoma (SBP) of the upper cervical spine is a rare diagnosis. The exact role of surgery for SBP remains unclear.

Case Summary: We present the first case of SBP of the C2. Read More

View Article and Full-Text PDF

Case Report: Multiple Vertebral Compression Fractures in 14-Year-Old Children With Multiple Myeloma.

Front Oncol 2021 25;11:662169. Epub 2021 Mar 25.

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.

Multiple myeloma (MM) is a neoplastic disorder characterized by clonal proliferation of malignant plasma cells derived from B cells in bone marrow. Pediatric MM is rare with only approximately 0.3% of cases diagnosed before the age of 30. Read More

View Article and Full-Text PDF

Isolated Leptomeningeal Recurrence of Multiple Myeloma.

Neurohospitalist 2021 Jan 1;11(1):87-88. Epub 2020 Jul 1.

Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

View Article and Full-Text PDF
January 2021

Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.

Front Immunol 2021 30;12:651751. Epub 2021 Mar 30.

Laboratory of Tumor Biology and Immunotherapy, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia.

Natural killer cells possess key regulatory function in various malignant diseases, including acute myeloid leukemia. NK cell activity is driven by signals received through ligands binding activating or inhibitory receptors. Their activity towards elimination of transformed or virally infected cells can be mediated through MICA, MICB and ULBP ligands binding the activating receptor NKG2D. Read More

View Article and Full-Text PDF

Retrospective review of accelerated daratumumab administration.

J Oncol Pharm Pract 2021 Apr 17:10781552211009967. Epub 2021 Apr 17.

Pharmacy Department, 1859Beth Israel Deaconess Medical Center, Boston, MA, USA.

Daratumumab is an anti-CD38 monoclonal antibody approved for multiple myeloma. The initial infusion is administered over a median of 7.5 hours with subsequent infusions given over 3 to 4 hours. Read More

View Article and Full-Text PDF

Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.

Ann Hematol 2021 Apr 17. Epub 2021 Apr 17.

Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.

The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple myeloma is controversial. We analyzed the results of 205 patients transplanted in one center during 2000-2017. Transplantation was performed on 75 patients without a previous autologous SCT (upfront-allo), on 74 as tandem transplant (auto-allo), and on 56 patients after relapse. Read More

View Article and Full-Text PDF

Radiation pneumonitis and chemotherapy in a patient with multiple myeloma.

Lancet 2021 Apr;397(10283):1484

Service de Réanimation médicale, Centre Hospitalier Universitaire de Caen Normandie, Caen, France.

View Article and Full-Text PDF

Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis.

Leuk Res 2021 Mar 31;106:106565. Epub 2021 Mar 31.

Department of Hematology, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Shushan District, Hefei City, Anhui Province, 230032, China. Electronic address:

Background: Numerous long non-coding RNAs (lncRNAs) are reported to affect the progression of multiple myeloma (MM). This study is aimed to explore the role and downstream mechanism of lncRNA LINC01003 in MM.

Materials And Methods: Xenograft tumor assay was used to assess the function of LINC01003 in MM in vivo. Read More

View Article and Full-Text PDF

Circular RNA_0000190 and its target microRNA-767-5p are dysregulated, and they are related to risk stratification as well as prognosis in multiple myeloma patients.

Ir J Med Sci 2021 Apr 16. Epub 2021 Apr 16.

Department of Hematology, The First People's Hospital of Jingmen, No. 67 Xiangshan Avenue, Jingmen, 448000, People's Republic of, China.

Background: This study aimed to explore the correlation between circular RNA_0000190 (circ_0000190) and microRNA-767-5p (miR-767-5p), and their correlations with biochemical indices, risk stratification, treatment response, and survival in multiple myeloma (MM) patients.

Methods: Bone marrow (BM) plasma cells of 86 MM patients (during standard diagnostic procedures) and 30 healthy donors (HDs) (examination of the eligibility for BM transplantation) were obtained, among which circ_0000190 and miR-767-5p expressions were detected using reverse transcription quantitative polymerase chain reaction. In MM patients, Durie-Salmon stage and International Staging System (ISS) stage were assessed. Read More

View Article and Full-Text PDF

Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens.

Ann Hematol 2021 Apr 16. Epub 2021 Apr 16.

Department of Hematology, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa, Chiba, 277-8577, Japan.

View Article and Full-Text PDF

Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma - Single center experience.

Transfus Apher Sci 2021 Apr 3:103127. Epub 2021 Apr 3.

İnönü University, Turgut Özal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address:

Objective: Peripheral blood stem cell transplantation is frequently used in the treatment of various hematological malignancies after intensive chemotherapy. The primary aim of our study is to compare the amount of collected CD34+ cells and engraftment times in patients mobilized with filgrastim or lenograstim.

Material And Methods: Demographic and clinical data of multiple myeloma (MM) and lymphoma patients who underwent autologous transplantation and mobilized with G-CSF (filgrastim or lenograstim) without chemotherapy were collected retrospectively. Read More

View Article and Full-Text PDF

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options.

Blood Rev 2021 Feb 9:100808. Epub 2021 Feb 9.

Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA, USA.

Despite the recent introduction of new therapies for multiple myeloma (MM), it remains an incurable disease. As MM progresses, patients experience cycles of relapse and remission, with remission periods becoming increasingly shorter as the disease becomes less treatment-sensitive. The treatment of relapsed refractory MM (RRMM) remains a significant clinical challenge. Read More

View Article and Full-Text PDF
February 2021

Novel antigens of CAR T cell therapy: New roads; old destination.

Transl Oncol 2021 Apr 13;14(7):101079. Epub 2021 Apr 13.

Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; Research and Development Center of Biotechnology, Tarbiat Modares University, Tehran, Iran. Electronic address:

Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However, this picture is not as colorful when it comes to the treatment of solid tumors mainly due to the lack of definitive tumor antigens, as well as the immunosuppressive tumor microenvironments and poor CAR-T infiltration. The recent developments in bioinformatics and cell biology, such as single-cell RNA sequencing, have offered silver linings in the subject of tumor antigen discovery. Read More

View Article and Full-Text PDF

Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.

Bioorg Med Chem 2021 Apr 3;39:116133. Epub 2021 Apr 3.

Center for Drug Discovery, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, PR China. Electronic address:

Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14-23, 38-41, 43, 47-49) bearing triazolopyridazine motif exhibited remarkable BRD4 protein inhibitory activities. Read More

View Article and Full-Text PDF

Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders.

Microvasc Res 2021 Apr 13:104171. Epub 2021 Apr 13.

Department of Health Promotion and Child Care, Internal Medicine and Medical Specialties, Università degli Studi di Palermo, Palermo, Italy. Electronic address:

Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classification 1970) divided the primary hyperviscosity syndromes in polycythaemic, sclerocytemic and sieric. Recent and personal laboratory observations have highlighted an unexpected behaviour of the erythrocyte deformability observed in some haematological disorders such as polycythemia vera, multiple myeloma and monoclonal gammopathy of undetermined significance. Read More

View Article and Full-Text PDF

SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma.

Clin Biochem 2021 Apr 13. Epub 2021 Apr 13.

Department of Clinical and Experimental Medicine, University of Messina, Messina Italy.

Objectives: Sirtuins comprise seven family elements (SIRT1-7) involved in various cell signalling pathways comprising cancer inhibition and tumorigenesis. The present study aims to evaluate SIRT2 and SIRT3 gene expression and potential redox reactions in patients with multiple myeloma (MM) at onset and its correlation with disease status, extent and presence of organ damage secondary to myeloma.

Design & Methods: Total RNA was extracted from 17 MM patients and 10 controls to assess gene expression using real-time PCR. Read More

View Article and Full-Text PDF

Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma.

Ann Hematol 2021 Apr 15. Epub 2021 Apr 15.

Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.

View Article and Full-Text PDF

Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.

ACS Pharmacol Transl Sci 2021 Apr 4;4(2):713-729. Epub 2021 Feb 4.

College of Medicine and Public Health, Flinders University, Bedford Park, South Australia 5042, Australia.

P-Glycoprotein is a well-known drug transporter associated with chemotherapy resistance in a number of cancers, but its role in modulating proteasome inhibitor efficacy in multiple myeloma is not well understood. The second-generation proteasome inhibitor carfilzomib is thought to be a substrate of P-glycoprotein whose efficacy may correlate with P-glycoprotein activity; however, research concerning the first-in-class proteasome inhibitor bortezomib is inconsistent. We show that while P-glycoprotein gene expression increases with the disease stages leading to multiple myeloma it does not affect the survival of newly diagnosed patients treated with bortezomib. Read More

View Article and Full-Text PDF

Vanishing Bone As the Presenting Feature of Multiple Myeloma.

Cureus 2021 Mar 12;13(3):e13861. Epub 2021 Mar 12.

Department of Radiology, National Cancer Institute, Nagpur, IND.

A 47-year-old female presented with a minimally displaced fracture of proximal one-third of the shaft of the humerus that she suffered two months before and managed conservatively with a Plaster of Paris (POP) slab. An X-ray performed after six weeks showed complete vanishing of the proximal third portion of humerus due to massive osteolysis and generalized osteopenia. On examination, there was a soft tissue swelling over the proximal part of the left arm with painful and limited range of motion of the left shoulder. Read More

View Article and Full-Text PDF

Myeloma-bone marrow adipocyte axis in tumour survival and treatment response.

Br J Cancer 2021 Apr 15. Epub 2021 Apr 15.

Maine Medical Center Research Institute, Scarborough, ME, USA.

Multiple myeloma is an incurable cancer of the bone marrow that is dependent on its microenvironment, including bone marrow adipocytes (BMAds). Here, we discuss our findings that the reciprocal interaction of myeloma cells and BMAds, leads to myeloma cell survival and induces metabolic dysfunction and senescence-associated secretory phenotype in BMAds. Read More

View Article and Full-Text PDF

Evaluation of patients diagnosed with psoriasis and multiple myeloma after autologous stem cell transplantation.

Transfus Apher Sci 2021 Apr 8:103137. Epub 2021 Apr 8.

University of Health Sciences, Bozyaka Education and Traing Hospital, Department of Hematology, Izmir, Turkey.

Introduction: The secretion of monoclonal immunoglobulins increase in chronic inflammatory disorders such as chronic infections and autoimmune diseases. This risk is further increased by the biological agents used in the treatment of autoimmune diseases such as psoriasis. Hematological malignancies occurring in patients with psoriasis provides an opportunity to evaluate the effect of autologous or allogeneic stem cell transplantation in this immune-mediated disease. Read More

View Article and Full-Text PDF